Conjugate Vaccine Market, by Product Types (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine), by Disease Indication (Pneumococcal, Influenza, Meningococcal, and Typhoid), by Pathogen Type (Bacterial and Viral), by Patient Type (Pediatric and Adults), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Jun 2019 |
  • Pages : 186 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Conjugate Vaccine Market Insights

Increasing collaborations among key players to develop and introduce vaccines for pneumococcal and meningococcal diseases in the market and ongoing clinical trial studies on pneumococcal vaccines are expected to drive growth of the global conjugated vaccines market in the near future. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

The global conjugate vaccine market was valued at US$ 12,977.2 million in 2018, and is expected to witness a CAGR of 9.6% during the forecast period (2018–2026).

Figure 1. Global Conjugate Vaccine Market value Analysis (US$ Mn), By Product Type

Conjugate Vaccine  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of various infectious diseases is expected to drive growth of the global conjugate vaccine market

According to World Health Organization (WHO), till November 2017, over 280 million people have been vaccinated with meningococcal A conjugate vaccine in 21 African belt countries. Moreover, increasing prevalence of meningococcal infections is a major factor expected to aid in growth of the global conjugate vaccine market. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015, around 375 total cases of meningococcal disease were reported in the U.S.

Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077. The candidate has been developed for the prevention of invasive disease and pneumonia, caused by Streptococcus pneumonia serotypes for adults aged 18 years and older.

Increasing approval for meningococcal conjugate vaccine candidates is expected to boost growth of the global conjugate vaccine market. For instance, in December 2016, Pfizer Inc. received an European Commission (EC) approval for its expanded indication for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine), which is indicated for active immunization against invasive meningococcal disease (IMD), caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.

Global Conjugate vaccine Market- Regional Analysis

North America is expected to witness lucrative growth in the global conjugate vaccine market, owing to increasing prevalence of diseases in the U.S. For instance, according to National Health Interview Survey (NHIS) 2015 reports, risk of pneumococcal disease among adults aged 19-64 years were increased by 2.8% as compared 2014 in the U.S. Moreover, presence of major vaccines manufacturers such as Pfizer Inc. and others in the region is also expected to boost the regional market share during the forecast period

Asia Pacific is also expected to drive growth of the global conjugate vaccine market, owing to increasing initiatives by healthcare provider and hospitals. Moreover, various national governments in the region are focusing on vaccination programs to fulfil the demand. For instance, National Immunization Program by Queensland Government in Australia and Mission Indradhanush vaccination program in India work to provide vaccination among children throughout the respective nations.

Europe is expected to show significant growth rate, owing to rising initiatives by key players in development of conjugate vaccine systems for various purposes. For instance, in March 2015, Pfizer Inc. (U.S.) received the European Commission approval for an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.

Figure 2: Global Conjugate Vaccine Market Value (US$ Mn), By Region (2026)

Conjugate Vaccine  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Global Conjugate Vaccine Market - Competitive Landscape

Key players operating in the global conjugate vaccine market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.

Market Dynamics

Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 – 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.

Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.

This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.

Key features of the study:

  • This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global conjugate vaccine market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Conjugate vaccine market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate vaccine market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate vaccine market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate vaccine market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate vaccine market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type:
        • Pediatric
        • Adults
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type:
        • Pediatric
        • Adults
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Monovalent Conjugate Vaccine
        • Multivalent Conjugate Vaccine
      • By Disease Indication:
        • Pneumococcal
        • Influenza
        • Meningococcal
        • Typhoid
      • By Pathogen Type:
        • Bacterial
        • Viral
      • By Patients Type :
        • Pediatric
        • Adults
  • Company Profiles
    • Sanofi S.A *
      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Pathogen Type
      • Market Snippet, By Patient Type
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Product Pipeline Analysis
    • Investments and Government Initiatives
    • GAVI and PATH Program Details
    • Merger and Acquisition
    • Regulatory Scenario
    • PORTER’S Five Forces
    • PEST Analysis
  4. Global Conjugate Vaccine Market, By Product Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Monovalent Conjugate Vaccine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Multivalent Conjugate Vaccine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Conjugate Vaccine Market, By Disease Indication, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Pneumococcal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Influenza
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Meningococcal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Typhoid
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Conjugate Vaccine Market, By Pathogen Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Bacterial
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Viral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Conjugate Vaccine Market, By Patient Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Pediatric
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Adult
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  8. Global Conjugate Vaccine Market, By Regions, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2016 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Pathogen Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Patient Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Sanofi S.A.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bharat Biotech
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Serum institute of India Pvt. Ltd
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biological E. Limited.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bio-Med
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 33 figures on "Conjugate Vaccine Market” - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.